Studies have found that there are several ways to ultimately attenuate renal IRI by inhibiting the activation of the NLRP3 inflammasome, such as using hydrogen sulfide (H2S) [49], -hydroxybutyrate (-OHB) treatment [50], inhibiting mTORC1 with activated protein C (aPC) [51], and promoting zinc ion influx in renal TECs with transient receptor potential-6 (TRPC6) [52]
It also significantly reduced inflammatory markers TNF-alpha and destructive enzymes MMP-2/MMP-9
This protection allows for direct cellular uptake, bypassing the traditional barriers that limit conventional supplementation effectiveness
Reported Limitations and Considerations in GHK-Cu Research Gaps in the Current Evidence Base Despite a substantial pre-clinical record, GHK-Cu lacks large-scale human clinical trial data for most reported applications
Avoid if allergic to Lidocaine
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
